A Comparative Randomized Prospective Study to Evaluate Efficacy and Safety of Combination of Tamsulosin and Tadalafil vs. Tamsulosin or Tadalafil Alone in Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia

被引:64
作者
Singh, Dig Vijay [1 ]
Mete, Uttam Kumar [1 ]
Mandal, Arup Kumar [1 ]
Singh, Shrawan Kumar [1 ]
机构
[1] Post Grad Inst Med Educ & Res, Dept Urol, Chandigarh 160012, India
关键词
Tamsulosin; Tadalafil; Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms; Erectile Dysfunction; Medical Therapy; COMBINED ORAL-THERAPY; ERECTILE DYSFUNCTION; PHOSPHODIESTERASE-5; INHIBITORS; INTEGRATED APPROACH; SILDENAFIL CITRATE; SEXUAL DYSFUNCTION; ALPHA-BLOCKERS; MEN; EPIDEMIOLOGY; ALFUZOSIN;
D O I
10.1111/jsm.12357
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and erectile dysfunction are common disorders of advancing age. Aim To evaluate the efficacy and safety of tamsulosin and tadalafil in patients with LUTS due to BPH. Methods In this prospective randomized study, 133 men complaining of LUTS due to BPH were included. Forty-five patients received tamsulosin 0.4 mg/day alone (Group A), 44 patients received tadalafil 10 mg/day (Group B), and combination therapy (tamsulosin and tadalafil both) was instituted in 44 patients (Group C). After a 2-week medication free run-in period, they were evaluated for International Prostatic Symptom Score (IPSS), International Index of Erectile Function score (IIEF5), quality of life (IPSS QoL), maximum urinary flow rate (Qmax), post-void residual urine (PVR) volume, and safety parameters before and at 3 months of treatment. Main Outcome Measures There were primary (IPSS, IPSS QoL index, Qmax, and PVR) and secondary (erectile function [EF] domain scores from IIEF5) efficacy end points. Safety assessment included laboratory tests and patient's reporting of adverse event. Results A significant improvement in IPSS score was observed in all the 3 groups A, B, and C (-50.90%, P<0.05; -33.50%, P<0.05; and -53.90%, P<0.05, respectively). IIEF5 score increased significantly in these three groups (+39.28%, P<0.05; +45.96%, P<0.05; and +60.23%, P<0.05, respectively). A significant increase in Qmax and decrease in PVR were also observed (33.99%, P<0.05; 29.78%, P<0.05; and 37.04%, P<0.05) and (-60.90%, P<0.05; -49.45%, P<0.05; and -62.97%, P<0.05, respectively). The QoL scores improved significantly (-73.35%, P<0.05; -70.26%, P<0.05; and -79.65%, P<0.05, respectively). Side effects were dyspepsia, heartburn, headache, flushing, myalgia, and backache. Adverse effect dropout was 3.7%. No participant experienced any severe or serious adverse events. Conclusions In patients with LUTS due to BPH, tamsulosin and tadalafil alone or in combination cause a significant improvement in patients with LUTS. Their EF also improves with these medications. The improvement is better with combination therapy compared with single agent alone.
引用
收藏
页码:187 / 196
页数:10
相关论文
共 50 条
  • [31] Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study
    Pattanaik, Smita
    Sandhu, Harbhupinder Singh
    Mavuduru, Ravimohan Suryanarayan
    Singh, Shrawan Kumar
    Mandal, Arup Kumar
    INDIAN JOURNAL OF UROLOGY, 2019, 35 (01) : 25 - 33
  • [32] Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia
    Griwan, Mahavir Singh
    Karthikeyan, Y. R.
    Kumar, Mandeep
    Singh, Bikram Jit
    Singh, Santosh Kumar
    UROLOGY ANNALS, 2014, 6 (03) : 181 - 186
  • [33] Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication
    Madani, Ali Hamidi
    Afsharimoghaddam, Amin
    Roushani, Ali
    Farzan, Alireza
    Asadollahzade, Ahmad
    Shakiba, Maryam
    INTERNATIONAL BRAZ J UROL, 2012, 38 (01): : 33 - 39
  • [34] Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
    Yoshida, Masaki
    Origasa, Hideki
    Seki, Narihito
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2017, 9 (03) : 176 - 186
  • [35] Efficacy and safety of combination of tadalafil and aspirin versus tadalafil or aspirin alone in patients with vascular erectile dysfunction: a comparative randomized prospective study
    Bayraktar, Zeki
    Albayrak, Selami
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (09) : 1491 - 1499
  • [36] Effectiveness of the addition of tadalafil to tamsulosin in the treatment of acute urinary retention in patients with benign prostatic hyperplasia: A randomized clinical trial
    Aval, Hamidreza Baghani
    Ameli, Zeinab
    Ameli, Mojtaba
    UROLOGIA JOURNAL, 2018, 85 (02) : 51 - 54
  • [37] Study of phosphodiesterase 5 inhibitors and a-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia
    Sun, Yi
    Peng, Bo
    Lei, Guo-Lin
    Wei, Qiang
    Yang, Lu
    MINERVA UROLOGICA E NEFROLOGICA, 2020, 72 (01) : 13 - 21
  • [38] Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo- and tamsulosin-controlled 12-week study in Asian men
    Yokoyama, Osamu
    Yoshida, Masaki
    Kim, Sae Chul
    Wang, Chii-Jye
    Imaoka, Takeshi
    Morisaki, Yoji
    Viktrup, Lars
    INTERNATIONAL JOURNAL OF UROLOGY, 2013, 20 (02) : 193 - 201
  • [39] Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH.: Pilot study
    Bechara, Amado
    Romano, Salomon
    Casabe, Adolfo
    Haime, Sergio
    Dedola, Pablo
    Hernandez, Cecilia
    Rey, Horacio
    JOURNAL OF SEXUAL MEDICINE, 2008, 5 (09) : 2170 - 2178
  • [40] Comparison of tamsulosin and Finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients
    Lee, E
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2002, 30 (06) : 584 - 590